FDA biologics center director Peter Marks doubled down on the agency’s stance that its emergency use authorization guidance, hung up at the White House, simply lays out stricter criteria for potential COVID-19 vaccines that industry has been aware of for months, despite suggestions from the White House that the guidance is a political ploy. Marks’ comments echo statements made by former FDA chiefs and public health experts who over the past few days have underscored that vaccine makers are aware...